The Cooper Companies, Inc. $COO Position Boosted by Waverly Advisors LLC

Posted by Stanley Muller on Sep 12th, 2026

Waverly Advisors LLC raised its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO – Free Report) by 1,180.4% during the 2nd quarter, Holdings Channel reports. The fund owned 58,360 shares of the medical device company’s stock after purchasing an additional 53,802 shares during the period. Waverly Advisors LLC’s holdings in Cooper Companies were worth $4,185,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Cooper Companies by 48.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock worth $1,890,000 after purchasing an additional 7,363 shares during the period. First Trust Advisors LP lifted its stake in shares of Cooper Companies by 115.8% in the 2nd quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company’s stock worth $9,702,000 after acquiring an additional 73,165 shares during the period. Cresset Asset Management LLC acquired a new stake in shares of Cooper Companies in the 2nd quarter worth approximately $291,000. Cerity Partners LLC boosted its holdings in shares of Cooper Companies by 4.4% in the second quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company’s stock valued at $1,272,000 after acquiring an additional 757 shares in the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in shares of Cooper Companies by 2.8% in the second quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company’s stock valued at $2,551,000 after acquiring an additional 973 shares in the last quarter. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Trading Down 0.5%

Cooper Companies stock opened at $53.91 on Friday. The firm has a market cap of $10.51 billion, a price-to-earnings ratio of 18.40, a price-to-earnings-growth ratio of 1.45 and a beta of 0.82. The Cooper Companies, Inc. has a 1 year low of $51.01 and a 1 year high of $89.83. The firm’s 50 day moving average price is $71.62 and its two-hundred day moving average price is $69.70. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.22.

Cooper Companies (NASDAQ:COO – Get Free Report) last announced its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The company had revenue of $1.07 billion during the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, research analysts predict that The Cooper Companies, Inc. will post 4.53 EPS for the current fiscal year.

Cooper Companies declared that its board has authorized a share buyback plan on Wednesday, September 9th that authorizes the company to repurchase $3.00 billion in shares. This repurchase authorization authorizes the medical device company to buy up to 22.7% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Analysts Set New Price Targets

Several brokerages recently commented on COO. Wall Street Zen cut Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday. Robert W. Baird set a $61.00 price target on Cooper Companies and gave the company a “neutral” rating in a research note on Thursday. The Goldman Sachs Group set a $61.00 price target on Cooper Companies in a research report on Wednesday, May 27th. William Blair lowered Cooper Companies from an “outperform” rating to a “market perform” rating in a report on Thursday. Finally, Wells Fargo & Company set a $61.00 target price on Cooper Companies and gave the stock an “equal weight” rating in a report on Thursday. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $71.47.

Get Our Latest Stock Analysis on Cooper Companies

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

Cooper Companies Profile

(Free Report)

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.